Boone Capital Management LLC purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 113,173 shares of the company's stock, valued at approximately $12,978,000. Kymera Therapeutics comprises about 3.0% of Boone Capital Management LLC's investment portfolio, making the stock its 14th biggest position. Boone Capital Management LLC owned about 0.14% of Kymera Therapeutics at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in KYMR. Smartleaf Asset Management LLC boosted its holdings in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after buying an additional 424 shares during the last quarter. Larson Financial Group LLC increased its holdings in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after buying an additional 349 shares during the last quarter. Osaic Holdings Inc. raised its position in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after acquiring an additional 1,083 shares in the last quarter. GAMMA Investing LLC raised its position in Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company's stock worth $52,000 after acquiring an additional 98 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Kymera Therapeutics in the fourth quarter valued at $63,000.
Insider Activity
In other news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the business's stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the completion of the sale, the director owned 240,123 shares in the company, valued at $25,573,099.50. The trade was a 86.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Bruce N. Jacobs sold 77,109 shares of the company's stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total value of $8,864,450.64. Following the completion of the transaction, the chief financial officer directly owned 244,883 shares in the company, valued at $28,151,749.68. The trade was a 23.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 3,587,629 shares of company stock valued at $386,183,782. Company insiders own 15.98% of the company's stock.
Kymera Therapeutics Price Performance
KYMR stock opened at $125.55 on Thursday. Kymera Therapeutics, Inc. has a one year low of $39.84 and a one year high of $130.05. The stock has a market cap of $10.44 billion, a price-to-earnings ratio of -38.75 and a beta of 1.95. The company has a fifty day moving average price of $111.63 and a two-hundred day moving average price of $93.15.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company's revenue was up 465.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.95) earnings per share. Research analysts anticipate that Kymera Therapeutics, Inc. will post -3.75 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. Oppenheimer reissued an "outperform" rating and issued a $125.00 price objective on shares of Kymera Therapeutics in a research report on Wednesday, August 5th. Citigroup reaffirmed a "buy" rating on shares of Kymera Therapeutics in a report on Thursday, August 6th. Barclays raised their target price on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. TD Cowen raised Kymera Therapeutics to a "strong-buy" rating in a research report on Monday. Finally, Deutsche Bank Aktiengesellschaft started coverage on Kymera Therapeutics in a research report on Thursday, July 30th. They set a "hold" rating and a $120.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $125.65.
Check Out Our Latest Research Report on Kymera Therapeutics
Kymera Therapeutics Company Profile
(
Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
